Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Johnston, Stephen; Kilburn, Lucy; Ellis, Paul; Dodwell, David; Cameron, David; Hayward, Larry; Im, Young‐Hyuck; Braybrooke, Jeremy; Murray Brunt, Adrian; Cheung, Kwok‐Leung; Jyothirmayi, R.; Robinson, A.; Wardley, Andrew; Wheatley, Duncan; Howell, Anthony; Coombes, Gill; Sergenson, Nicole; Sin, Hui-Jung; Folkerd, Elizabeth; Dowsett, Mitch; M. Bliss, Judith

doi:10.1016/s1470-2045(13)70322-x

Public

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Published in The Lancet Oncology • Jul 28, 2013

Authors:

Stephen Johnston

Lucy Kilburn

Paul Ellis

Abstract

BACKGROUND: The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the ste...

Subject

Anastrozole

Exemestane

Fulvestrant

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!